The Expert Consensus Guideline Series
Pharmacotherapy of Depressive Disorders in Older Patients

George S. Alexopoulos, M.D.
Cornell Institute of Geriatric Psychiatry
and Weill Medical College of Cornell University

Ira R. Katz, M.D., Ph.D.
University of Pennsylvania
and Philadelphia VA Medical Center

Charles F. Reynolds, III, M.D.
Western Psychiatric Institute and Clinic
and University of Pittsburgh School of Medicine

Daniel Carpenter, Ph.D.
Comprehensive NeuroScience, Inc.

John P. Docherty, M.D.
Comprehensive NeuroScience, Inc.

Editing and Design. Ruth Ross, M.A., David Ross, M.A., M.C.E., Ross Editorial

Acknowledgments. The authors thank Paola Breton, of Expert Knowledge Systems, for managing the data collection.

Reprints. Reprints may be obtained by sending requests with a shipping/handling fee of $12.95 per copy to: Expert Knowledge Systems, 21 Bloomingdale Road, White Plains, NY 10605. For pricing on bulk orders of 50 copies or more, please call Expert Knowledge Systems at (914) 997-4005. For more information on the Expert Consensus Guidelines, visit the Web site www.psychguides.com.

Support. This project was supported by NIMH grants P30-MH49762, P30-MH52247, and P30-MH52129, and by unrestricted educational grants from Forest Pharmaceuticals, Inc. and Pfizer, Inc.

Continuing Medical Education. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by the Annenberg Center for Health Sciences at Eisenhower and Comprehensive NeuroScience. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians. The Annenberg Center designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
The Expert Consensus Panel for Pharmacotherapy of Depressive Disorders in Older Patients

The following participants in the Expert Consensus Survey were identified from several sources: the NIMH list of grant recipients for research in geriatric psychiatric disorders and the membership of the American Association for Geriatric Psychiatry. Of the 50 experts to whom we sent the survey, 50 (100%) replied. The recommendations in the guidelines reflect the aggregate opinions of the experts and do not necessarily reflect the opinion of each individual on each question.

Peter Aupperle, M.D.  
Robert Wood Johnson Medical School

John Kasckow, M.D.  
University of Cincinnati

Bruce G. Pollock, M.D., Ph.D.  
University of Pittsburgh

Stephen Bartels, M.D.  
Dartmouth

Gary J. Kennedy, M.D.  
Montefiore Medical Center

Peter Rabins, M.D.  
Johns Hopkins University

Dan G. Blazer, M.D.  
Duke University

Harold G. Koenig, M.D.  
Duke University

K. Ranga Rama Krishnan, M.D.  
Duke University

William Bondareff, M.D.  
University of Southern California

Anand Kumar, M.D.  
UCLA NeuroPsychiatric Institute

Robert G. Robinson, M.D.  
University of Iowa

Soo Borson, M.D.  
University of Washington

Mark Kunik, M.D.  
Baylor College of Medicine, Houston VAMC

Jules Rosen, M.D.  
WPIU University of Pittsburgh

John C. S. Breitner, M.D.  
Johns Hopkins University

Helen Lavretsky, M.D.  
UCLA

Barry W. Rovner, M.D.  
Jefferson Medical College

Christopher C. Colenda, M.D.  
Michigan State University

Ira Lesser, M.D.  
Harbor UCLA Medical Center

Carl Salzman, M.D.  
Massachusetts Mental Health Center

Devangere P. Devanand, M.D.  
Columbia University

Jeffrey Marc Lyness, M.D.  
University of Rochester

Lon S. Schneider, M.D.  
University of Southern California

Alastair John Flint, M.D.  
University of Toronto

Robert S. Marin, M.D.  
University of Pittsburgh

Alan J. Sholomskas, M.D.  
Yale University

Mary Ganguli, M.D.  
University of Pittsburgh

Barnett S. Meyers, M.D.  
Cornell University

David C. Steffens, M.D.  
Duke University

Gary L. Gottlieb, M.D.  
Partners Healthcare Boston

Jacob E. Mintzer, M.D.  
Medical University of South Carolina

Joel E. Streim, M.D.  
University of Pennsylvania

Blaine S. Greenwald, M.D.  
Hillside Hosp–Long Island Jewish Med Ctr

Gary Moak, M.D.  
University of Massachusetts

Trey Sunderland, M.D.  
National Institutes of Mental Health

George Grossberg, M.D.  
St. Louis University

Benoit H. Mulsant, M.D.  
University of Pittsburgh

Larry Tune, M.D.  
Emory University

Hugh Hendrie, M.D.  
Indiana University

Greer M. Murphy, M.D.  
Stanford University

Richard C. Veith, M.D.  
University of Washington

Nathan Herrmann, M.D.  
University of Toronto

Paul A. Newhouse, M.D.  
University of Vermont

Jerome A. Yesavage, M.D.  
Stanford University

Lissy F. Jarvik, M.D.  
UCLA

David W. Oslin, M.D.  
University of Pennsylvania

George S. Zubenko, M.D., Ph.D.  
University of Pittsburgh

Dilip V. Jeste, M.D.  
University of California

Thomas E. Oxman, M.D.  
Dartmouth
Contents

Expert Consensus Panel...........................................................................................................2
Introduction: Methods, Summary, and Commentary..............................................................5

GUIDELINES

Guideline Organization and Key Terms ................................................................................19

I. ASSESSMENT OF DEPRESSION IN OLDER PATIENTS

Guideline 1: Initial Assessment Procedures.........................................................................20
Guideline 2: Most Important Comorbid Conditions to Assess .............................................21
Guideline 3: Most Important Symptoms in Diagnosing Depression of an Older Patient ........................................................................................22
Guideline 4: Need for Referral for Psychiatric Care...........................................................23
Guideline 5: Suicide Risk ................................................................................................23

II. ACUTE TREATMENT STRATEGIES AND MEDICATION SELECTION

Guideline 6: Unipolar Nonpsychotic Major Depressive Disorder.......................................24
Guideline 7: Unipolar Psychotic Major Depressive Disorder ..............................................25
Guideline 8: Use of Electroconvulsive Therapy in Older Patients With Unipolar Major Depressive Disorder ....................................................26
Guideline 9: Dysthymic Disorder .......................................................................................26
Guideline 10: Minor Depressive Disorder .........................................................................27
Guideline 11: Initial Treatment Strategies for Depression Associated With an External Stresor ..............................................................................27
Guideline 12: Choice of Specific Medications Within Classes ..............................................28
Guideline 13: Choice of Psychosocial Interventions .............................................................29
Guideline 14: Evaluating Treatment Outcomes ...................................................................29

III. DOSING AND DURATION OF TREATMENT

Guideline 15: Adequate Dose of Antidepressants .................................................................30
Guideline 16: Duration of Adequate Antidepressant Trial....................................................31
Guideline 17: Adequate Dose of Antipsychotics .................................................................31
IV. TREATMENT RESISTANCE

Guideline 18: Inadequate Response to Initial Antidepressant:
General Strategies ........................................................................................................ 32

Guideline 19: Little or No Response to Initial Antidepressant .................................. 32

Guideline 20: Partial Response to Initial Antidepressant .............................................. 33

Guideline 21: Complementary or Novel Therapies
for Treatment-Refractory Depression ........................................................................ 33

Guideline 22: Insomnia ................................................................................................. 34

Guideline 23: Strategies for Treating Residual Anxiety ................................................ 34

V. STRATEGIES FOR CONTINUATION AND MAINTENANCE TREATMENT

Guideline 24: Dosage and Duration of Continuation/Maintenance Treatment .......... 35

Guideline 25: Continuation/Maintenance Treatment After ECT .............................. 37

Guideline 26: Mood Stabilizers in Continuation/Maintenance Treatment .................. 38

VI. SPECIAL TREATMENT ISSUES

Guideline 27: Medical Comorbidity ............................................................................ 39

Guideline 28: Managing Depression Associated With a Medication .......................... 42

Guideline 29: Combining Medications in Older Patients .......................................... 43

SURVEY RESULTS

Expert Survey Results and Guideline References ......................................................... 44

GUIDE FOR PATIENTS AND FAMILIES ..................................................................... 83